French pharmaceutical company Servia as well as generic producers including Israel’s Teva received formal objections from the European Commission concerning alleged entry delay of the generic form of cardiovascular drug perindopril. By both buying up rare technology needed to create the drug and settling out of court with would-be generic producers, the Commission believes Servier abused its dominant market position by restricting competitive business. Similar pay-for-delay practices were denounced only a few days ago in the Commission’s objections issued to pharmaceutical powerhouse Lundbeck.
Full content: EU
Related content: The EC Pharmaceutical Inquiry: Behind the Headlines, What is the Real Story on Innovation and Generic Competition in Pharmaceuticals?
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
ConocoPhillips Acquires Marathon Oil for $22.5 Billion in Major Energy Sector Consolidation
May 29, 2024 by
CPI
Judge Denies Amazon’s Bid to Dismiss FTC Lawsuit Over Prime Membership Practices
May 29, 2024 by
CPI
Germany and France Advocate for Major EU Competition Reform
May 29, 2024 by
CPI
Equifax Accused of Monopolizing Employment Verification Market in New Suit
May 29, 2024 by
CPI
Car Battery Makers to Challenge EU Cartel Charges in Brussels
May 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI